- Amid data readouts from adagrasib, sitravatinib programs, Mirati Therapeutics Inc MRTX has appointed David Meek as Chief Executive Officer, effective immediately.
- Related: Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards.
- Mr. Meek will also join the Company's Board of Directors.
- Earlier CEO Charles Baum led the Company for nine years.
- Dr. Baum will continue to lead the research and development (R&D) organization as president, founder, and head of R&D and remain on the Company's Board of Directors.
- David Meek most recently served as president, CEO, and board member of FerGene.
- Related: Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients.
- Price Action: MRTX stock is up 4.79% at $182.38 during the market session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
